Page last updated: 2024-11-04

1,7-dimethylxanthine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

1,7-dimethylxanthine is a synthetic compound that belongs to the xanthine family, a group of naturally occurring purine alkaloids. It is closely related to caffeine and theophylline, differing only in the methylation pattern on the xanthine molecule. 1,7-dimethylxanthine exhibits pharmacological effects similar to caffeine, such as stimulation of the central nervous system and the cardiovascular system. It is known to increase heart rate, blood pressure, and alertness. 1,7-dimethylxanthine is studied for its potential therapeutic applications, particularly in the treatment of respiratory diseases, as it has bronchodilating properties, relaxing smooth muscles in the airways. However, its clinical use is limited due to potential side effects, such as insomnia, anxiety, and tremors. The synthesis of 1,7-dimethylxanthine involves methylation of the xanthine molecule at the 1 and 7 positions. The compound has a molecular weight of 180.16 g/mol and a melting point of 340°C. It is a white crystalline solid, soluble in water and alcohol. 1,7-dimethylxanthine is also found in trace amounts in some natural sources, such as tea and coffee, though its concentration is significantly lower compared to caffeine and theophylline.'

1,7-dimethylxanthine : A dimethylxanthine having the two methyl groups located at positions 1 and 7. It is a metabolite of caffeine and theobromine in animals. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID4687
CHEMBL ID1158
CHEBI ID25858
SCHEMBL ID232702
SCHEMBL ID4651937
MeSH IDM0075717

Synonyms (102)

Synonym
bdbm50042210
1,7-dimethyl-2,3,6,7-tetrahydro-1h-purine-2,6-dione
BRD-K24084088-001-02-2
KBIO1_000081
DIVK1C_000081
EU-0100389
1,7-dimethylxanthine, ~98%, solid
1h-purine-2,6-dione, 3,7-dihydro-1,7-dimethyl-
1,7-dimethyl-3h-purine-2,6-dione
LOPAC0_000389
nsc 400018
brn 0197907
einecs 210-271-9
xanthine, 1,7-dimethyl-
3,7-dihydro-1,7-dimethyl-1h-purine-2,6-dione
CHEBI:25858 ,
eur j pharmacol 179: 295 (1990)
p-xanthine
1,7-dimethyl-3,7-dihydro-1h-purine-2,6-dione
lopac-d-5385
NCGC00015347-01
BSPBIO_002448
SPECTRUM5_001506
IDI1_000081
paraxanthine
611-59-6
1,7-dimethylxanthine
1h-purine-2, 3,7-dihydro-1,7-dimethyl-
nsc-400018
nsc400018
inchi=1/c7h8n4o2/c1-10-3-8-5-4(10)6(12)11(2)7(13)9-5/h3h,1-2h3,(h,9,13
pxt ,
smr000326790
MLS000859929
NCGC00093817-02
NCGC00093817-04
KBIO3_001668
KBIOGR_001614
SPBIO_001806
SPECTRUM3_000774
SPECTRUM4_001207
NINDS_000081
SPECTRUM2_001733
SPECTRUM2300170
NCGC00093817-03
NCGC00093817-01
NCGC00015347-02
D 5385
NCGC00015347-07
CHEMBL1158 ,
paraxanthine(72%)
HMS500E03
HMS3261M19
HMS2231K19
CCG-39489
NCGC00015347-05
NCGC00015347-04
NCGC00015347-03
NCGC00015347-06
q3565y41v7 ,
5-26-13-00554 (beilstein handbook reference)
unii-q3565y41v7
FT-0673516
FT-0632550
LP00389
AKOS015913484
HMS3370A12
caffeine impurity f [ep impurity]
paraxanthine [inci]
caffeine monohydrate impurity f [ep impurity]
SCHEMBL232702
SCHEMBL4651937
NCGC00261074-01
tox21_500389
caffeine impurity f
1,7-dimethyl-xanthine
1,7-dimethyl-3,7-dihydro-1h-purine-2,6-dione #
dtxsid2052281 ,
cas-611-59-6
NCGC00357087-01
tox21_303803
dtxcid2030853
1,7-dimethyl-3,7-dihydro- 1h-purine-2,6-dione (caffeine impurity f), pharmaceutical secondary standard; certified reference material
mfcd00005727
AS-64037
1,7-dimethyl-3,7-dihydro-1h-purine-2,6-dione (paraxanthine; 1,7-dimethylxanthine)
SR-01000075184-1
sr-01000075184
HY-W016498
CS-W017214
paraxanthine (1,7-dimethylxanthine)
Q419223
3-(4-methoxy-1-naphthyl)acrylicacid
Z1255430986
BRD-K24084088-001-06-3
SDCCGSBI-0050376.P003
NCGC00015347-09
A853055
D94772
1,7-dimethylxanthine 100 microg/ml in acetonitrile
D5696
EN300-1666036

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Critical review of toxic manifestations due to exposure to relatively large doses of caffeine and theophylline indicates that such combined exposure may potentiate the toxic effects of either drug."( Methylxanthines: toxicity to humans. 3. Theobromine, paraxanthine and the combined effects of methylxanthines.
Stavric, B, 1988
)
0.27

Pharmacokinetics

ExcerptReferenceRelevance
"001) and no significant differences were observed in the pharmacokinetic data derived from the respective concentration-time curves."( The pharmacokinetics of caffeine and its dimethylxanthine metabolites in patients with chronic liver disease.
Chakraborty, J; Marks, V; Morgan, MY; Scott, NR; Stambuk, D, 1989
)
0.28
"The pharmacokinetic of paraxanthine, one of the primary metabolites of caffeine, is described for the first time."( Pharmacokinetics of paraxanthine, one of the primary metabolites of caffeine, in the rat.
Bonati, M; Bortolotti, A; Jiritano, L,
)
0.13
" The serum concentration-time curves for each animal were analyzed separately to estimate model-independent pharmacokinetic variables."( Comparative pharmacokinetics of caffeine and three metabolites in clinically normal horses and donkeys.
Matthews, NS; Mealey, KL; Peck, K; Taylor, TS, 1997
)
0.3
"Mean pharmacokinetic values for caffeine, theophylline, and paraxanthine did not differ significantly in horses, compared with donkeys."( Comparative pharmacokinetics of caffeine and three metabolites in clinically normal horses and donkeys.
Matthews, NS; Mealey, KL; Peck, K; Taylor, TS, 1997
)
0.3
" Serum concentrations of fluvoxamine, caffeine and paraxanthine were measured and standard pharmacokinetic parameters were calculated."( Lack of correlation between fluvoxamine clearance and CYP1A2 activity as measured by systemic caffeine clearance.
Dahlqvist, R; Hägg, S; Söderström, E; Spigset, O, 1999
)
0.3
" The validity of the human kinetic subfactor has been analysed in relation to CYP1A2 metabolism using published in vivo pharmacokinetic parameters selected to reflect chronic exposure (metabolic and total clearances and area under the plasma concentration-time curve: CLm, CL and AUC) and acute exposure (the peak plasma concentration, C(max))."( Uncertainty factors for chemical risk assessment. human variability in the pharmacokinetics of CYP1A2 probe substrates.
Dorne, JL; Renwick, AG; Walton, K, 2001
)
0.31
"The stimulant effect of caffeine, as an additive in diacetylmorphine preparations for study purposes, may interfere with the pharmacodynamic effects of diacetylmorphine."( Population pharmacokinetics of caffeine and its metabolites theobromine, paraxanthine and theophylline after inhalation in combination with diacetylmorphine.
Beijnen, JH; de Jonge, ME; den Hoed, R; Hendriks, VM; Huitema, AD; Sparidans, RW; van den Brink, W; van Ree, JM; Zandvliet, AS, 2005
)
0.33
"Among nonsmokers, the peak concentration (C(max)) and area under concentration-time curve from 0 to infinity [AUC(0-infinity)] of tizanidine did not differ significantly between females and males."( Effects of gender and moderate smoking on the pharmacokinetics and effects of the CYP1A2 substrate tizanidine.
Backman, JT; Neuvonen, PJ; Schröder, MT, 2008
)
0.35
" This method can be applied to the pharmacokinetic study of norfloxacin and enoxacin after repeated administration to assess changes in CYP1A2 activity in healthy subjects."( A simple chromatographic method for determining norfloxacin and enoxacin in pharmacokinetic study assessing CYP1A2 inhibition.
Homma, M; Kobayashi, D; Kobayashi, T; Kohda, Y; Momo, K, 2011
)
0.37
") decreased metabolism of caffeine to paraxanthine, with overall decrease in caffeine clearance (6-20%), increase in area under the curve (AUC; 7-24%) and plasma half-life (t(1/2) 14-16%)."( Effects of the aqueous extract from Salvia miltiorrhiza Bunge on caffeine pharmacokinetics and liver microsomal CYP1A2 activity in humans and rats.
Wang, X; Yeung, JH, 2010
)
0.36
"This was a cross-over pharmacokinetic study in 30 healthy male subjects who received a single oral 100mg caffeine dose after 24-h caffeine abstinence or after maintaining their regular caffeine intake (no caffeine abstinence)."( Pharmacokinetics of caffeine in plasma and saliva, and the influence of caffeine abstinence on CYP1A2 metrics.
Gross, AS; McLachlan, AJ; Perera, V; Xu, H, 2011
)
0.37
"This study sought to assess the pharmacokinetic (PK) changes of caffeine and its CYP1A2 metabolites across the 3 trimesters of pregnancy."( Pregnancy-induced changes in the pharmacokinetics of caffeine and its metabolites.
Campbell, SC; Clark, EA; Schoen, K; Sherwin, CM; Spigarelli, MG; Stockmann, C; Tak, C; Varner, MW; Yu, T, 2016
)
0.43
"This pharmacokinetic (PK) drug-interaction trial investigated the effects of repeated dosing of a plant-derived pharmaceutical formulation of highly purified cannabidiol (CBD; Epidiolex in the United States and Epidyolex in Europe; 100 mg/mL oral solution) on caffeine clearance via modulation of cytochrome P450 (CYP) 1A2 activity in healthy adults."( A Phase 1 Open-Label, Fixed-Sequence Pharmacokinetic Drug Interaction Trial to Investigate the Effect of Cannabidiol on the CYP1A2 Probe Caffeine in Healthy Subjects.
Critchley, D; Tayo, B; Thai, C, 2021
)
0.62

Compound-Compound Interactions

ExcerptReferenceRelevance
" In the current study, stepwise injection analysis (SWIA) was successfully combined with single-drop liquid microextraction (SDLME) and solvent exchange procedure."( Stepwise injection potentiometric determination of caffeine in saliva using single-drop microextraction combined with solvent exchange.
Bulatov, A; Kirsanov, D; Medinskaia, K; Nikolaeva, L; Timofeeva, I, 2016
)
0.43

Bioavailability

ExcerptReferenceRelevance
" An analysis of the published literature showed that the absorption, bioavailability and route of excretion were generally similar between humans and the test species, for each probe substrate."( Uncertainty factors for chemical risk assessment: interspecies differences in the in vivo pharmacokinetics and metabolism of human CYP1A2 substrates.
Dorne, JL; Renwick, AG; Walton, K, 2001
)
0.31
" The bioavailability was approximately 60%."( Population pharmacokinetics of caffeine and its metabolites theobromine, paraxanthine and theophylline after inhalation in combination with diacetylmorphine.
Beijnen, JH; de Jonge, ME; den Hoed, R; Hendriks, VM; Huitema, AD; Sparidans, RW; van den Brink, W; van Ree, JM; Zandvliet, AS, 2005
)
0.33

Dosage Studied

ExcerptRelevanceReference
" These findings suggest that CA pharmacokinetic parameters can be estimated using a simplified three-point blood sampling procedure following a single oral load and that the serum PX/CA or (PX + TB + TP)/CA ratio in a single blood sample taken 2 or 4 h after dosing provides a useful indicator for the assessment of hepatic drug-oxidizing capacity, N-demethylation, in decompensated liver cirrhosis."( A simple useful method for the determination of hepatic function in patients with liver cirrhosis using caffeine and its three major dimethylmetabolites.
Fukao, K; Ishikawa, A; Iwasaki, Y; Misawa, S; Osada, A; Tanaka, E; Tsuji, K; Yamamoto, Y, 1992
)
0.28
" However, the effects of the four agents on the clonal survival of irradiated cells failed to correlate with the extent of override, both in terms of the relative effects of the four agents and the dose-response relationships; at a concentration of 1 mM only caffeine was found to potentiate cell killing as well as causing block override, whilst at higher concentrations all the agents had a significant effect on survival but little or no further influence on the degree of block override."( Override of the radiation-induced mitotic block in human tumour cells by methylxanthines and its relationship to the potentiation of cytotoxicity.
Musk, SR; Steel, GG, 1990
)
0.28
" Venous blood samples were obtained before dosing and at minutes 5, 10, 15, 30, 45, 60, 90, 120, 150, and 180."( Effect of paraxanthine on FFA mobilization after intravenous caffeine administration in humans.
Brown, DD; Hetzler, RK; Knowlton, RG; Perkins, RM; Somani, SM, 1990
)
0.28
"Some recent epidemiologic studies have reported a nonlinear dose-response in the relationship between coffee consumption and health risks, such that the risks increase disproportionately to the increase in dose."( Dose-dependency of caffeine metabolism with repeated dosing.
Benowitz, NL; Brown, CR; Denaro, CP; Jacob, P; Wilson, M, 1990
)
0.28
" bolus dosing both separately and concomitantly to New Zealand White rabbits."( Caffeine and paraxanthine pharmacokinetics in the rabbit: concentration and product inhibition effects.
Dorrbecker, BR; Dorrbecker, SH; Ferraina, RA; Kramer, PA, 1987
)
0.27
" The objective of this study was to validate urine caffeine metabolite ratios versus stable isotope-labeled caffeine clearance under different caffeine dosing conditions."( Validation of urine caffeine metabolite ratios with use of stable isotope-labeled caffeine clearance.
Benowitz, NL; Denaro, CP; Jacob, P; Wilson, M, 1996
)
0.29
" The stable isotope technique allowed simultaneous oral dosing of caffeine and measurement of caffeine metabolite ratios and caffeine clearance, the latter reflecting CYP1A2 activity."( Validation of urine caffeine metabolite ratios with use of stable isotope-labeled caffeine clearance.
Benowitz, NL; Denaro, CP; Jacob, P; Wilson, M, 1996
)
0.29
" Caffeine, theophylline, and paraxanthine shifted the dose-response curve for adenosine at the A1, A2A, and A2B receptors."( Comparison of the potency of adenosine as an agonist at human adenosine receptors expressed in Chinese hamster ovary cells.
Fredholm, BB; Irenius, E; Kull, B; Schulte, G, 2001
)
0.31
" The variability in CYP1A2 activity in healthy adults, based on data after oral and intravenous dosage (CLm, CL and AUC), ranged from 34 to 42%."( Uncertainty factors for chemical risk assessment. human variability in the pharmacokinetics of CYP1A2 probe substrates.
Dorne, JL; Renwick, AG; Walton, K, 2001
)
0.31
"Riluzole is used in a fixed dosing schedule of 50 mg twice daily to treat patients with amyotropic lateral sclerosis (ALS), one form of motor neurone disease."( Association between CYP1A2 activity and riluzole clearance in patients with amyotrophic lateral sclerosis.
Groeneveld, GJ; Guchelaar, HJ; Kalmijn, S; Spieksma, M; van den Berg, LH; van Kan, HJ, 2005
)
0.33
" Careful dosing of tizanidine is warranted in small females, whereas male smokers can require higher than average doses."( Effects of gender and moderate smoking on the pharmacokinetics and effects of the CYP1A2 substrate tizanidine.
Backman, JT; Neuvonen, PJ; Schröder, MT, 2008
)
0.35
" Dosage adjustments may be required for drugs that are substrates of CYP3A4 (e."( Interaction profile of armodafinil with medications metabolized by cytochrome P450 enzymes 1A2, 3A4 and 2C19 in healthy subjects.
Darwish, M; Hellriegel, ET; Kirby, M; Robertson, P, 2008
)
0.35
"Accurate quantitative measurement of drugs and their metabolites is important as this can be used to establish long-term abuse of illicit materials as well as establish accurate drug dosing for legal therapeutics."( Simultaneous multiplexed quantification of caffeine and its major metabolites theobromine and paraxanthine using surface-enhanced Raman scattering.
Alharbi, O; Goodacre, R; Xu, Y, 2015
)
0.42
" Overall, the population norm of the salivary metabolic ratio in a Singaporean Chinese population established in this study is distinct from individuals with liver disease or mild abnormal liver function tests and provides the benchmark for dosage adjustments of drugs metabolized by CYP1A2."( Establishing population distribution of drug-metabolizing enzyme activities for the use of salivary caffeine as a dynamic liver function marker in a Singaporean Chinese population.
Chia, HY; Ho, HK; Yau, WP, 2016
)
0.43
"This pharmacokinetic (PK) drug-interaction trial investigated the effects of repeated dosing of a plant-derived pharmaceutical formulation of highly purified cannabidiol (CBD; Epidiolex in the United States and Epidyolex in Europe; 100 mg/mL oral solution) on caffeine clearance via modulation of cytochrome P450 (CYP) 1A2 activity in healthy adults."( A Phase 1 Open-Label, Fixed-Sequence Pharmacokinetic Drug Interaction Trial to Investigate the Effect of Cannabidiol on the CYP1A2 Probe Caffeine in Healthy Subjects.
Critchley, D; Tayo, B; Thai, C, 2021
)
0.62
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
central nervous system stimulantAny drug that enhances the activity of the central nervous system.
human xenobiotic metaboliteAny human metabolite produced by metabolism of a xenobiotic compound in humans.
human blood serum metaboliteAny metabolite (endogenous or exogenous) found in human blood serum samples.
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
dimethylxanthine
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (12)

PathwayProteinsCompounds
Metabolism14961108
Biological oxidations150276
Phase I - Functionalization of compounds69175
Cytochrome P450 - arranged by substrate type30110
Xenobiotics450
Aromatic amines can be N-hydroxylated or N-dealkylated by CYP1A2110
Caffeine Pathway, Pharmacokinetics66
Caffeine Metabolism821
caffeine biosynthesis II (via paraxanthine)011
caffeine biosynthesis II (via paraxanthine)012
caffeine degradation IV (bacteria, via demethylation and oxidation)016
caffeine degradation III (bacteria, via demethylation)521
Caffeine and theobromine metabolism011

Protein Targets (33)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency6.30960.003245.467312,589.2998AID2517
endonuclease IVEscherichia coliPotency10.00000.707912.432431.6228AID1708
thioredoxin reductaseRattus norvegicus (Norway rat)Potency1.25890.100020.879379.4328AID588453
Microtubule-associated protein tauHomo sapiens (human)Potency3.16230.180013.557439.8107AID1468
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency39.81070.011212.4002100.0000AID1030
thyroid stimulating hormone receptorHomo sapiens (human)Potency39.81070.001318.074339.8107AID926; AID938
regulator of G-protein signaling 4Homo sapiens (human)Potency0.16830.531815.435837.6858AID504845
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency0.24340.001530.607315,848.9004AID1224841
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency0.02240.035520.977089.1251AID504332
Bloom syndrome protein isoform 1Homo sapiens (human)Potency0.63100.540617.639296.1227AID2364; AID2528
peripheral myelin protein 22 isoform 1Homo sapiens (human)Potency84.921423.934123.934123.9341AID1967
chromobox protein homolog 1Homo sapiens (human)Potency112.20200.006026.168889.1251AID540317
importin subunit beta-1 isoform 1Homo sapiens (human)Potency10.00005.804836.130665.1308AID540263
snurportin-1Homo sapiens (human)Potency10.00005.804836.130665.1308AID540263
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency39.81070.031610.279239.8107AID884; AID885
lamin isoform A-delta10Homo sapiens (human)Potency0.00450.891312.067628.1838AID1487
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Inositol monophosphatase 1Rattus norvegicus (Norway rat)Potency31.62281.000010.475628.1838AID901
GABA theta subunitRattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (43)

Assay IDTitleYearJournalArticle
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID453742Inhibition of Escherichia coli recombinant N-terminal hexahistidine-tagged CTP synthetase expressed in Escherichia coli BL21 (DE3) assessed as inhibition of CTP formation in Hepes buffer at pH 8 by continuous spectrophotometric assay in presence of 150 mM2010Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1
Inhibition of CTP synthase from Escherichia coli by xanthines and uric acids.
AID30807Binding affinity against Adenosine A2 receptor in rat striatal membranes using [3H]5'-(N-ethylcarboxamido)-adenosine (NECA) as the ligand1993Journal of medicinal chemistry, Oct-29, Volume: 36, Issue:22
Synthesis of paraxanthine analogs (1,7-disubstituted xanthines) and other xanthines unsubstituted at the 3-position: structure-activity relationships at adenosine receptors.
AID453745Inhibition of Escherichia coli recombinant N-terminal hexahistidine-tagged CTP synthetase expressed in Escherichia coli BL21 (DE3) assessed as inhibition of CTP formation in Hepes buffer at pH 8 by continuous spectrophotometric assay in presence of 10 mM 2010Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1
Inhibition of CTP synthase from Escherichia coli by xanthines and uric acids.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID453743Inhibition of Escherichia coli recombinant N-terminal hexahistidine-tagged CTP synthetase expressed in Escherichia coli BL21 (DE3) assessed as inhibition of CTP formation in TAPS buffer at pH 8.5 by continuous spectrophotometric assay in presence of 150 m2010Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1
Inhibition of CTP synthase from Escherichia coli by xanthines and uric acids.
AID453746Inhibition of Escherichia coli recombinant N-terminal hexahistidine-tagged CTP synthetase expressed in Escherichia coli BL21 (DE3) assessed as inhibition of CTP formation in TAPS buffer at pH 8.5 by continuous spectrophotometric assay in presence of 10 mM2010Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1
Inhibition of CTP synthase from Escherichia coli by xanthines and uric acids.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID31881Binding affinity at Adenosine A1 receptor in rat brain cortical membrane using [3H]N6-R-phenylisopropyladenosine (R-PIA) as radioligand1993Journal of medicinal chemistry, Oct-29, Volume: 36, Issue:22
Synthesis of paraxanthine analogs (1,7-disubstituted xanthines) and other xanthines unsubstituted at the 3-position: structure-activity relationships at adenosine receptors.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (284)

TimeframeStudies, This Drug (%)All Drugs %
pre-199049 (17.25)18.7374
1990's68 (23.94)18.2507
2000's70 (24.65)29.6817
2010's72 (25.35)24.3611
2020's25 (8.80)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 29.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index29.56 (24.57)
Research Supply Index5.82 (2.92)
Research Growth Index4.66 (4.65)
Search Engine Demand Index36.91 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (29.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials39 (13.18%)5.53%
Reviews12 (4.05%)6.00%
Case Studies3 (1.01%)4.05%
Observational0 (0.00%)0.25%
Other242 (81.76%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]